The firm will use Jefferson Health’s providers, care coordinators and patients to evaluate the blood-based MCED test’s safety and efficacy, the report said.
Jefferson Health serves more than 125,000 adults who are eligible for cancer screening. The health system and Exact Sciences plan to publish the results of the research, according to the report.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
